Pharmaceutical Manufacturing Market Size To Hit US$ 1,190.16 Billion By 2030

The global pharmaceutical manufacturing market size is expected to hit around USD 1,190.16 billion by 2030 and progressing a CAGR of 12.8% over the forecast period 2022 to 2030.

Pharmaceutical Manufacturing Market Size 2020 to 2030

The on pharmaceutical manufacturing Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/1191

Scope of Market

Report Highlights	Details
Market Size	US$ 1,190.16 Billion by 2030
Growth Rate	CAGR of 12.8% From 2021 to 2030
Base Year	2021
Historic Data	2017 to 2020
Forecast Period	2021 to 2030
Segments Covered	Drug Development, Route of Administration, Formulation, Therapy
Regional Scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)

A recent report provides crucial insights along with application based and forecast information in the Global Pharmaceutical manufacturing Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Pharmaceutical manufacturing market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Pharmaceutical manufacturing market are included as given below:

Pharmaceutical manufacturing Market Key Players

GlaxoSmithKline plc
Merck & Co., Inc.
Eli Lilly and Company
Johnson & Johnson
Hoffmann-La Roche Ltd.
Lonza
Pfizer, Inc.
Sanofi SA
Novartis AG
AstraZeneca

Market Segments

By Drug Development Type

In-house
Outsource

By Route of Administration

Topical
Oral
Inhalations
Parenteral
Others

By Formulation

Injectable
Tablets
Suspensions
Capsules
Sprays
Others

By Therapy

Diabetes
Cardiovascular Diseases
Respiratory Diseases
Cancer
Pain
Others

By Geography

North America

U.S.
Canada

Europe

Germany
France
United Kingdom
Rest of Europe

Asia Pacific

China
Japan
India
Southeast Asia
Rest of Asia Pacific

Latin America

Brazil
Rest of Latin America

Middle East & Africa (MEA)

GCC
North Africa
South Africa
Rest of Middle East & Africa

Report Objectives

To define, describe, and forecast the global pharmaceutical manufacturing market based on product, and region
To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the pharmaceutical manufacturing market

Table of Content

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Pharmaceutical Manufacturing Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Pharmaceutical Manufacturing Market

5.1. Covid-19: Pharmaceutical Manufacturing Industry Impact
5.2. Pharmaceutical Manufacturing Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Pharmaceutical Manufacturing Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Pharmaceutical Manufacturing Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Pharmaceutical Manufacturing Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increasing prevalence of chronic ailments
6.1.1.2. Growing geriatric population
6.1.2. Market Restraints
6.1.2.1. Stringent Regulations
6.1.3. Market Opportunities
6.1.3.1. Increasing prevalence of chronic ailments
6.1.3.2. Growing geriatric population

Chapter 7. Global Pharmaceutical Manufacturing Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Pharmaceutical Manufacturing Market Revenue by Market Players (2016 -2019)
7.1.1.2. Pharmaceutical Manufacturing Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Drug Development Type Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Pharmaceutical Manufacturing Market, By Drug Development Type

8.1. Pharmaceutical Manufacturing Market, by Drug Development Type, 2017-2030
8.1.1. In-house
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Outsource
8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Pharmaceutical Manufacturing Market, By Route of Administration

9.1. Pharmaceutical Manufacturing Market, by Route of Administration, 2017-2030
9.1.1. Topical
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Oral
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Inhalations
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Parenteral
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Pharmaceutical Manufacturing Market, By Formulation

10.1. Pharmaceutical Manufacturing Market, by Formulation, 2017-2030
10.1.1. Injectable
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Tablets
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Suspensions
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Capsules
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Sprays
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Pharmaceutical Manufacturing Market, By Therapy

11.1. Pharmaceutical Manufacturing Market, by Therapy, 2017-2030
11.1.1. Diabetes
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Cardiovascular Diseases
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Respiratory Diseases
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Cancer
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. Pain
11.1.5.1. Market Revenue and Forecast (2017-2030)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Pharmaceutical Manufacturing Market, Regional Estimates and Trend Forecast

12.1. North America
12.1.1. Market Revenue Forecast by Drug Development Type(2017-2030)
12.1.2. Market Revenue Forecast by Route of Administration(2017-2030)
12.1.3. Market Revenue Forecast by Formulation (2017-2030)
12.1.4. Market Revenue Forecast by Therapy (2017-2030)
12.1.5. U.S
12.1.5.1. Market Revenue Forecast (2017-2030)
12.1.6. Canada
12.1.6.1. Market Revenue Forecast (2017-2030)
12.2. Europe
12.2.1. Market Revenue Forecast by Drug Development Type (2017-2030)
12.2.2. Market Revenue Forecast by Route of Administration (2017-2030)
12.2.3. Market Revenue Forecast by Formulation (2017-2030)
12.2.4. Market Revenue Forecast by Therapy (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue Forecast (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue Forecast (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue Forecast (2017-2030)
12.2.8. Rest of EU
12.2.8.1. Market Revenue Forecast (2017-2030)
12.3. Asia Pacific (APAC)
12.3.1. Market Revenue Forecast by Drug Development Type (2017-2030)
12.3.2. Market Revenue Forecast by Route of Administration (2017-2030)
12.3.3. Market Revenue Forecast by Formulation (2017-2030)
12.3.4. Market Revenue Forecast by Therapy (2017-2030)
12.3.5. China
12.3.5.1. Market Revenue Forecast (2017-2030)
12.3.6. India
12.3.6.1. Market Revenue Forecast (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue Forecast (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue Forecast (2017-2030)
12.4. LATAM
12.4.1. Market Revenue Forecast by Drug Development Type (2017-2030)
12.4.2. Market Revenue Forecast by Route of Administration (2017-2030)
12.4.3. Market Revenue Forecast by Formulation (2017-2030)
12.4.4. Market Revenue Forecast by Therapy (2017-2030)
12.4.5. Brazil
12.4.5.1. Market Revenue Forecast (2017-2030)
12.4.6. Rest of LATAM
12.4.6.1. Market Revenue Forecast (2017-2030)
12.5. Middle East and Africa (MEA)
12.5.1. Market Revenue Forecast by Drug Development Type (2017-2030)
12.5.2. Market Revenue Forecast by Route of Administration (2017-2030)
12.5.3. Market Revenue Forecast by Formulation (2017-2030)
12.5.4. Market Revenue Forecast by Therapy (2017-2030)
12.5.5. GCC
12.5.5.1. Market Revenue Forecast (2017-2030)
12.5.6. North Africa
12.5.6.1. Market Revenue Forecast (2017-2030)
12.5.7. South Africa
12.5.7.1. Market Revenue Forecast (2017-2030)
12.5.8. Rest of MEA
12.5.8.1. Market Revenue Forecast (2017-2030)

Chapter 13. Company Profiles

13.1. GlaxoSmithKline plc
13.1.1. Company Overview, Business Information, Regional Presence
13.1.2. Product Portfolio Analysis
13.1.2.1. Product Details, Specification, Formulation
13.1.3. Revenue, Price, and Gross Margin (2015-2020)
13.1.4. Recent Developments and Strategies
13.2. Merck & Co., Inc.
13.2.1. Company Overview, Business Information, Regional Presence
13.2.2. Product Portfolio Analysis
13.2.2.1. Product Details, Specification, Formulation
13.2.3. Revenue, Price, and Gross Margin (2015-2020)
13.2.4. Recent Developments and Strategies
13.3. Eli Lilly and Company
13.3.1. Company Overview, Business Information, Regional Presence
13.3.2. Product Portfolio Analysis
13.3.2.1. Product Details, Specification, Formulation
13.3.3. Revenue, Price, and Gross Margin (2015-2020)
13.3.4. Recent Developments and Strategies
13.4. Johnson & Johnson
13.4.1. Company Overview, Business Information, Regional Presence
13.4.2. Product Portfolio Analysis
13.4.2.1. Product Details, Specification, Formulation
13.4.3. Revenue, Price, and Gross Margin (2015-2020)
13.4.4. Recent Developments and Strategies
13.5. F. Hoffmann-La Roche Ltd.
13.5.1. Company Overview, Business Information, Regional Presence
13.5.2. Product Portfolio Analysis
13.5.2.1. Product Details, Specification, Formulation
13.5.3. Revenue, Price, and Gross Margin (2015-2020)
13.5.4. Recent Developments and Strategies
13.6. Lonza
13.6.1. Company Overview, Business Information, Regional Presence
13.6.2. Product Portfolio Analysis
13.6.2.1. Product Details, Specification, Formulation
13.6.3. Revenue, Price, and Gross Margin (2015-2020)
13.6.4. Recent Developments and Strategies
13.7. Pfizer, Inc.
13.7.1. Company Overview, Business Information, Regional Presence
13.7.2. Product Portfolio Analysis
13.7.2.1. Product Details, Specification, Formulation
13.7.3. Revenue, Price, and Gross Margin (2015-2020)
13.7.4. Recent Developments and Strategies
13.8. Sanofi SA
13.8.1. Company Overview, Business Information, Regional Presence
13.8.2. Product Portfolio Analysis
13.8.2.1. Product Details, Specification, Formulation
13.8.3. Revenue, Price, and Gross Margin (2015-2020)
13.8.4. Recent Developments and Strategies
13.9. Novartis AG
13.9.1. Company Overview, Business Information, Regional Presence
13.9.2. Product Portfolio Analysis
13.9.2.1. Product Details, Specification, Formulation
13.9.3. Revenue, Price, and Gross Margin (2015-2020)
13.9.4. Recent Developments and Strategies
13.10. AstraZeneca
13.10.1. Company Overview, Business Information, Regional Presence
13.10.2. Product Portfolio Analysis
13.10.2.1. Product Details, Specification, Formulation
13.10.3. Revenue, Price, and Gross Margin (2015-2020)
13.10.4. Recent Developments and Strategies